Tri Locum Partners’s CorMedix CRMD Stock Holding History

Tri Locum Partners’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,812	Closed	-$58K	–	58
2022 Q4	$58K	Buy	+13,812	New	+$48.9K	0.02%	52

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Tri Locum Partners's CRMD Position: Q1 2023 in Review

Tri Locum Partners sold out of CorMedix (CRMD) in Q1 2023, closing a stake of 13,812 shares — an estimated $58K sold.

Tri Locum Partners first reported a position in CRMD in Q4 2022 and held it in 1 quarter. The position peaked at $58K in Q4 2022. 65 funds tracked by Wall St. Rank hold CRMD as of Q1 2023.

Tri Locum Partners reported no remaining CorMedix position as of Q1 2023 after selling out during the quarter.
Tri Locum Partners sold 13,812 CorMedix shares in Q1 2023, an estimated $58K.
Tri Locum Partners first reported a position in CorMedix in Q4 2022 and held it in 1 quarter.
Tri Locum Partners's CorMedix position peaked at $58K in Q4 2022.
65 funds tracked by Wall St. Rank held CorMedix as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.